Literature DB >> 19705921

Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.

Caroline Monchaud1, Pierre Marquet.   

Abstract

Part I of this article, which appeared in the previous issue of the Journal, reviewed calcineurin inhibitors--ciclosporin and tacrolimus. In part II, we review the pharmacokinetics and therapeutic drug monitoring of mycophenolate and mammalian target of rapamycin inhibitors--sirolimus and everolimus--in thoracic transplantation, and we provide an overall discussion and suggest various areas for future study.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19705921     DOI： 10.2165/11317240-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


  147 in total

1.  Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.

Authors:  Aurélie Prémaud; Yannick Le Meur; Jean Debord; Jean-Christophe Szelag; Annick Rousseau; Guillaume Hoizey; Olivier Toupance; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

Review 2.  Therapeutic drug monitoring of mycophenolate mofetil in transplantation.

Authors:  Teun van Gelder; Yann Le Meur; Leslie M Shaw; Michael Oellerich; David DeNofrio; Curtis Holt; David W Holt; Bruce Kaplan; Dirk Kuypers; Bruno Meiser; Burkhard Toenshoff; Richard D Mamelok
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

3.  Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients.

Authors:  M Baraldo; M Isola; M T Feruglio; A Francesconi; L Franceschi; V Tursi; U Livi; M Furlanut
Journal:  Transplant Proc       Date:  2005-06       Impact factor: 1.066

4.  Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.

Authors:  Lillian S L Ting; Nilufar Partovi; Robert D Levy; K Wayne Riggs; Mary H H Ensom
Journal:  Ann Pharmacother       Date:  2006-08-01       Impact factor: 3.154

5.  Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.

Authors:  Christiane Knoop; Philippe Thiry; Franck Saint-Marcoux; Annick Rousseau; Pierre Marquet; Marc Estenne
Journal:  Am J Transplant       Date:  2005-06       Impact factor: 8.086

6.  Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients.

Authors:  Victor William Armstrong; Gero Tenderich; Maria Shipkova; Amin Parsa; Reiner Koerfer; Heike Schröder; Michael Oellerich
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

7.  Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

Authors:  Howard J Eisen; Jon Kobashigawa; Anne Keogh; Robert Bourge; Dale Renlund; Robert Mentzer; Edwin Alderman; Hannah Valantine; Georges Dureau; Donna Mancini; Richard Mamelok; Robert Gordon; Whedy Wang; Mandeep Mehra; Maria Rosa Constanzo; Manfred Hummel; Jay Johnson
Journal:  J Heart Lung Transplant       Date:  2005-05       Impact factor: 10.247

8.  Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5.

Authors:  Nicolas Picard; Nassim Djebli; François-Ludovic Sauvage; Pierre Marquet
Journal:  Drug Metab Dispos       Date:  2006-12-06       Impact factor: 3.922

9.  Blood cyclosporine C0 and C2 concentrations and cytomegalovirus infections following lung transplantation.

Authors:  V Monforte; S Bullich; L Pou; C Bravo; R López; J Gavaldà; A Roman
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

Review 10.  Promise of Neoral C2, basiliximab, and everolimus in lung transplantation.

Authors:  C D Poirier
Journal:  Transplant Proc       Date:  2004-03       Impact factor: 1.066
View more
  12 in total

1.  Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.

Authors:  Brenda C M de Winter; Caroline Monchaud; Aurélie Prémaud; Christophe Pison; Romain Kessler; Martine Reynaud-Gaubert; Claire Dromer; Marc Stern; Romain Guillemain; Christiane Knoop; Marc Estenne; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.

Authors:  Reena Khanna; Brian G Feagan
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

Review 3.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 4.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 5.  Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis.

Authors:  Pamela Burcham; Lisa Sarzynski; Sabrina Khalfoun; Kimberly J Novak; Julie C Miller; Dmitry Tumin; Don Hayes
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

6.  Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.

Authors:  Caroline Monchaud; Brenda C de Winter; Christiane Knoop; Marc Estenne; Martine Reynaud-Gaubert; Christophe Pison; Marc Stern; Romain Kessler; Romain Guillemain; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

Review 7.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

8.  Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies.

Authors:  Yow-Wen Hsieh; Ching-Ya Huang; Shih-Ying Yang; Yu-Hsuan Peng; Chung-Ping Yu; Pei-Dawn Lee Chao; Yu-Chi Hou
Journal:  Sci Rep       Date:  2014-10-10       Impact factor: 4.379

9.  Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis.

Authors:  Santosh Peddi; Xiaoli Pan; John Andrew MacKay
Journal:  Front Pharmacol       Date:  2018-10-17       Impact factor: 5.810

10.  Clinical evaluation of pharmacists' interventions on multidisciplinary lung transplant outpatients' management: results of a 7-year observational study.

Authors:  Marion Duwez; Sébastien Chanoine; Marion Lepelley; Thi Ha Vo; Hélène Pluchart; Roseline Mazet; Benoit Allenet; Christophe Pison; Amandine Briault; Christelle Saint-Raymond; Boubou Camara; Johanna Claustre; Pierrick Bedouch
Journal:  BMJ Open       Date:  2020-11-27       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.